Get all your news in one place.
100’s of premium titles.
One app.
Start reading
Investors Business Daily
Investors Business Daily
Business
INVESTOR'S BUSINESS DAILY

Stocks Generating Improved Relative Strength: Protagonist Therapeutics

Protagonist Therapeutics saw a positive improvement to its Relative Strength (RS) Rating on Monday, rising from 69 to 74.

IBD's unique rating measures market leadership with a 1 (worst) to 99 (best) score. The rating shows how a stock's price movement over the last 52 weeks stacks up against all the other stocks in our database.

History shows that the best stocks typically have an RS Rating of at least 80 in the early stages of their moves. See if Protagonist Therapeutics can continue to rebound and hit that benchmark.

How To Invest In Stocks In Both Bull And Bear Markets

Protagonist Therapeutics is trying to complete a consolidation with a 48.89 buy point. See if it can clear the breakout price in volume at least 40% above average.

The company showed 0% EPS growth last quarter. Revenue increased -100%.

Protagonist Therapeutics earns the No. 14 rank among its peers in the Medical-Ethical Drugs industry group. Phibro Animal Health, Novartis ADR and Jazz Pharmaceuticals are among the top 5 highly rated stocks within the group.

RELATED:

Biotech And Pharmaceutical Industry And Stock News

Which Stocks Are Showing Improved Price Performance?

Why Should You Use IBD's Relative Strength Rating?

How Relative Strength Line Can Help You Judge A Stock

Ready To Grow Your Investing Skills? Join An IBD Meetup Group!

Sign up to read this article
Read news from 100’s of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.